Get the Stockscreener App
6.16
8.61%
-0.58
After Hours:
6.10
-0.06
-0.97%
CorMedix Inc stock is traded at $6.16, with a volume of 2.35M.
It is down -8.61% in the last 24 hours and down -40.54% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$6.74
Open:
$6.59
24h Volume:
2.35M
Relative Volume:
1.76
Market Cap:
$437.37M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-6.6957
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
-42.80%
1M Performance:
-40.54%
6M Performance:
-23.76%
1Y Performance:
+45.28%
1-Day Range:
$6.09
$6.64
1-Week Range:
$6.09
$9.25
52-Week Range:
$3.61
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
6.16 | 437.37M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.com
Long Term Trading Analysis for (CRMD) - Stock Traders Daily
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com South Africa
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines
CorMedix shares tumble after order delay - Investing.com
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges By Investing.com - Investing.com South Africa
CorMedix Dives on Results - Baystreet.ca
CorMedix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CorMedix Q4 Swings To Profit, Stock Down In Pre-market - Nasdaq
CorMedix Inc. Provides Preliminary Earnings Guidance for the First Half of 2025 - Marketscreener.com
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
CORMEDIX Earnings Results: $CRMD Reports Quarterly Earnings - Nasdaq
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
CorMedix Hits Major Milestone: First-Ever Profitable Quarter Signals Strong Growth Ahead - Stock Titan
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
CORMEDIX Earnings Preview: Recent $CRMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
CorMedix Inc expected to post earnings of 14 cents a shareEarnings Preview - TradingView
CRMD INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 20 Deadline in Securities Class Action – CRMD - Business Wire
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - The Manila Times
CorMedix Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Cormedix Inc. To Report Fourth Quarter And Full Year 2024 Financial Results And Provide A Corporate Update On March 25, 2025 - MENAFN.COM
(CRMD) Investment Report - news.stocktradersdaily.com
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):